Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cathasept is a catheter lock solution containing 4% tetrasodium edetate (tetra-sodium EDTA). It is designed to prevent microbial colonization and catheter-related bloodstream infections (CRBSIs) in patients undergoing maintenance hemodialysis via tunneled catheters. The solution exerts both antimicrobial and anticoagulant effects. By chelating divalent cations such as calcium and magnesium, it disrupts bacterial cell walls and biofilms while simultaneously inhibiting the calcium-dependent coagulation cascade. Developed by Covidien (formerly Tyco Healthcare), Cathasept has been evaluated in multicenter randomized controlled trials comparing its efficacy and safety against standard heparin locks, demonstrating a significant reduction in catheter colonization.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tetrasodium edetate.